Guard Therapeutics wins Nasdaq nod for continued listing tied to Disruptive Pharma deal

• Guard Therapeutics received conditional Nasdaq Stockholm clearance to keep its Nasdaq First North listing tied to its planned acquisition of Disruptive Pharma.
• The deal is structured as a non-cash share issue, with new consideration shares exchanged for Disruptive Pharma shares.
• On a full acquisition basis, Disruptive Pharma sellers would own about 55% of the enlarged group; existing Guard shareholders about 45%.
• Disruptive Pharma would become a subsidiary; Guard Therapeutics plans to rename to Disruptive Pharma AB once the deal closes.
• Listing clearance hinges on publishing a substantially unchanged company description, closing the transaction, meeting shareholder distribution requirements, and updating the website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guard Therapeutics International AB (publ) published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.